{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:03:43Z","timestamp":1744455823909,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Key Research and Development Program of China \u2018Precision Medicine Initiative\u2019","award":["2016YFC0900802"],"award-info":[{"award-number":["2016YFC0900802"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874242","31800979"],"award-info":[{"award-number":["81874242","31800979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFA0111600"],"award-info":[{"award-number":["2019YFA0111600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Hunan Province for outstanding Young Scholars","award":["2019JJ30040"],"award-info":[{"award-number":["2019JJ30040"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We sought to systematically investigate the effectiveness of secukinumab in psoriatic arthritis (PsA) patients who previously received TNFs inhibitor (TNFi) treatment and those who were TNFi na\u00efve.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Databases (PubMed, EMBase and Cochrane library) and ClinicalTrials.gov were searched from inception to 22 May 2020 for randomized control trails and observational studies of secukinumab, with or without a history of previous anti-TNFi treatment, in PsA. Effectiveness data were extracted and combined using a random-effects meta-analysis. The ACR20 and ACR50 (20% and 50% improvement in American College of Rheumatology response criteria) responses were the endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six randomized controlled trials that reported the effectiveness of secukinumab by previous anti-TNFi treatment were included. Among patients exposed to a prior anti-TNFi treatment (n\u2009=\u2009738), 33.7% (249\/738) of patients achieved an ACR20 response. In contrast, in the anti-TNFi-na\u00efve group (n\u2009=\u20091754), 49.8% (873\/1754) of patients achieved an ACR20 response. Prior treatment with anti-TNFi was significantly associated with a poorer response to secukinumab compared with the anti-TNFi-na\u00efve group with an effect size of 2.09 (95% CI: 1.69, 2.58).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Some patients benefit from switching from TNFi to secukinumab, but previous anti-TNFi treatment is associated with poorer effectiveness of secukinumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa449","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T19:10:49Z","timestamp":1593630649000},"page":"3657-3665","source":"Crossref","is-referenced-by-count":2,"title":["Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis"],"prefix":"10.1093","volume":"59","author":[{"given":"Yantao","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi\u2019ang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Central South University"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Central South University"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minxue","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Central South University"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University"},{"name":"Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2020121319242318900_keaa449-B1","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"2020121319242318900_keaa449-B2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2020121319242318900_keaa449-B3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2020121319242318900_keaa449-B4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"2020121319242318900_keaa449-B5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"2020121319242318900_keaa449-B6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2007","journal-title":"Br J Dermatol"},{"key":"2020121319242318900_keaa449-B7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2020121319242318900_keaa449-B8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2020121319242318900_keaa449-B9","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"on behalf of the MEASURE 1 and MEASURE 2 Study Groups. Secukinumab interleukin-17A inhibition in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"year":"2017","key":"2020121319242318900_keaa449-B10"},{"key":"2020121319242318900_keaa449-B11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40744-017-0076-0","article-title":"A review of the use of secukinumab for psoriatic arthritis","volume":"4","author":"Patel","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2020121319242318900_keaa449-B12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2016.02.1221","article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent","volume":"75","author":"Yamauchi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2020121319242318900_keaa449-B13","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020121319242318900_keaa449-B14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"key":"2020121319242318900_keaa449-B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020121319242318900_keaa449-B16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020121319242318900_keaa449-B17","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"2020121319242318900_keaa449-B18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2020121319242318900_keaa449-B19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2020121319242318900_keaa449-B20","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2020121319242318900_keaa449-B21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","article-title":"Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and \u2018Type 1\u2019 inflammatory gene expression","volume":"25","author":"Lew","year":"2004","journal-title":"Trends Immunol"},{"key":"2020121319242318900_keaa449-B22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2020121319242318900_keaa449-B23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"2020121319242318900_keaa449-B24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J Invest Dermatol"},{"key":"2020121319242318900_keaa449-B25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/ACI.0b013e3282ef869e","article-title":"Interleukin-17 in inflammatory skin disorders","volume":"7","author":"van Beelen","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2020121319242318900_keaa449-B26","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2020121319242318900_keaa449-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2020121319242318900_keaa449-B28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough in\ufb02iximab levels, pretreatment C reactive protein levels, and clinical response to in\ufb02iximab treatment in patients with rheumatoid arthritis","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020121319242318900_keaa449-B29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3657\/34890194\/keaa449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3657\/34890194\/keaa449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:25:08Z","timestamp":1607905508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/12\/3657\/5920574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa449","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,10]]}}}